Profound Medical Inc.

Profound Medical Inc. is a medical device company specializing in minimally invasive urological interventions. The company develops and markets the TULSA Procedure™ (Transurethral Ultrasound Ablation), an MRI-guided, incision-free ablative technology for prostate cancer and benign prostatic hyperplasia (BPH) treatment. The TULSA-PRO system uses real-time MRI temperature monitoring with closed-loop feedback control to deliver precise, targeted thermal ablation to prostate tissue while preserving quality of life outcomes including erectile function and urinary continence. Clinical evidence includes the CAPTAIN trial, a first-of-its-kind multi-center randomized controlled trial directly comparing TULSA to robotic radical prostatectomy, demonstrating statistically significant superiority in erectile function and continence preservation at six months. The technology supports flexible treatment planning with 360-degree targeting capability, enabling customizable ablation volumes for localized prostate cancer, radiorecurrent prostate cancer, BPH, and combined conditions. The TULSA Procedure is supported by 67+ peer-reviewed publications with durability data extending to five-year clinical outcomes. The system prioritizes patient safety through MRI guidance, real-time monitoring, and automated precision control to minimize complications. Profound Medical serves urology specialists and institutional healthcare providers, offering physician education through the PRO-Talk platform.